The present invention relates generally to novel recombinant polypeptides of Bahia grass pollen and to genetic sequences encoding same. More particularly, the present invention is directed to Pas n 1 polypeptides and derivatives, and fragments thereof and genetic sequences encoding same. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications including, but not limited to, applications in the context of conditions characterized by an aberrant, inappropriate or otherwise unwanted immune response to the Bahia grass pollen.

Genetic fusions of proteins, for example single-domain antibodies (sdAbs), with a positively-charged domain enhanced immobilization of active protein in a desired orientation.

Detection of grass pollen proteins such as Pas n 1, Sor h 1 and/or Cyn d 1 for the purpose of batch standardization of compositions comprising these grass pollen proteins, such as used for desensitization to these allergenic proteins. The methods may also be suitable for detecting or measuring levels of grass pollen proteins such as Pas n 1, Sor h 1 and/or Cyn d 1 in environmental samples such as air or water. Also provided is an antibody or antibody fragment engineered to bind Pas n 1 and one or a plurality of other grass pollen proteins such as Sor h 1 and/or Cyn d 1.

Detection of grass pollen proteins such as Pas n 1, Sor h 1 and/or Cyn d 1 for the purpose of batch standardization of compositions comprising these grass pollen proteins, such as used for desensitization to these allergenic proteins. The methods may also be suitable for detecting or measuring levels of grass pollen proteins such as Pas n 1, Sor h 1 and/or Cyn d 1 in environmental samples such as air or water. Also provided is an antibody or antibody fragment engineered to bind Pas n 1 and one or a plurality of other grass pollen proteins such as Sor h 1 and/or Cyn d 1.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The invention relates to a new gene that is able to provide plants with resistance against pathogens, more preferably Verticillium, Ralstonia or Fusarium. Said gene is typical for Brassicaceae and encodes for a proteins having a sequence as depicted in FIG. 7 or FIG. 2A. Also provided are methods for enhancing the pathogen resistance of plants, wherein said plants preferably are Brassicaceae, but wherein the resistance also is functional in other plants. Further provided are host cells with a nucleotide construct encoding said protein.

The invention relates to a new gene that is able to provide plants with resistance against pathogens, more preferably Verticillium, Ralstonia or Fusarium. Said gene is typical for Brassicaceae and encodes for a proteins having a sequence as depicted in FIG. 7 or FIG. 2A. Also provided are methods for enhancing the pathogen resistance of plants, wherein said plants preferably are Brassicaceae, but wherein the resistance also is functional in other plants. Further provided are host cells with a nucleotide construct encoding said protein.

The present invention provides for methods of identifying peptoid mimetics that will mimic B cell epitopes when delivered as vaccine compositions. One aspects of the invention is the use of monoclonal antibody that is broadly protective to select the mimetics, thereby identifying an epitope from a pathogen or other disease-causing agent that will be common among most or all variants of that pathogen or agent.

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.